Cereno Scientific to participate at the annual biotech partnering conference LSX Nordics
Cereno Scientific (Nasdaq First North: CRNO B), an innovative biotech pioneering treatments to enhance and extend life for people with rare cardiovascular and pulmonary diseases, today announced that the company will be participating at the annual partnering conference LSX Nordics on May 20-21, 2025, in Bergen, Norway. The LSX Nordics conference is the leading partnering and investment event in the Nordic and Baltic region.
“At Cereno Scientific, we are having a very busy spring as we are pursuing a multitude of key milestones for our drug development programs. We have so far showcased our positive progress in several US-based conferences and are now pleased to have the opportunity to engage also with stakeholders in Scandinavia. Interest continues to grow in Cereno Scientific’s innovative treatment approach, leveraging epigenetic modulation through HDAC inhibition, with our clinical drug candidates CS1 and CS014. We are well positioned to make a meaningful difference for people with underserved rare cardiovascular and pulmonary diseases and we look forward to continuing discussions with key industry stakeholders,” said Sten R. Sörensen, CEO of Cereno Scientific.
Sten R. Sörensen will also participate in a panel discussion titled “From Nordics to the World – Global Expansion for Homegrown Biotech” on May 21, at 11:10 in the Biotech Leaders area (Kongesal 1 & 2).
To schedule a meeting with Cereno Scientific register at https://informaconnect.com/lsx-nordic-congress/.
The LSX Nordic Congress is the leading partnering, strategy, and investment event serving the Nordic and Baltic region, with qualified 1:1 partnering at its core. The event gathers senior life science industry decision-makers from the region's most innovative biotech, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs.
For further information, please contact:
Tove Bergenholt, Head of IR & Communications
Email: [email protected]
Phone: +46 73- 236 62 46
Sten R. Sörensen, CEO
Email: [email protected]
Phone: +46 73-374 03 74
About Cereno Scientific AB
Cereno Scientific is pioneering treatments to enhance and extend life. Our innovative pipeline offers disease-modifying drug candidates to empower people suffering from rare cardiovascular and pulmonary diseases to live life to the full.
Lead candidate CS1 is an HDACi that works through epigenetic modulation, being developed as an effective and disease modifying treatment with a favorable safety and tolerability profile for rare disease Pulmonary Arterial Hypertension (PAH). A Phase IIa trial evaluating CS1’s safety, tolerability, and exploratory efficacy in patients with PAH demonstrated that CS1 has a favorable safety profile, is well-tolerated and showed a positive impact on exploratory clinical efficacy parameters. An Expanded Access Program enables patients that have completed the Phase IIa trial to gain access to CS1. CS014, in Phase I development, is a new chemical entity with disease-modifying potential. CS014 is a HDAC inhibitor with a multimodal mechanism of action as an epigenetic modulator having the potential to address the underlying pathophysiology of rare cardiovascular and pulmonary diseases with high unmet needs such as idiopathic pulmonary fibrosis (IPF). Cereno Scientific is also pursuing a preclinical program with CS585, an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular diseases. While CS585 has not yet been assigned a specific indication for clinical development, preclinical data indicates that it could potentially be used in indications like Thrombosis prevention without increased risk of bleeding and Pulmonary Hypertension.
The Company is headquartered in GoCo Health Innovation City, in Gothenburg, Sweden, and has a US subsidiary; Cereno Scientific Inc. based in Kendall Square, Boston, Massachusetts, US. Cereno Scientific is listed on the Nasdaq First North (CRNO B). The Certified Adviser is Carnegie Investment Bank AB, [email protected]. More information can be found on www.cerenoscientific.com.